Form 4: Arcus Biosciences President Sells Shares Under 10b5-1 Plan

Arcus Biosciences President Juan C. Jaen reported the sale of 96,859 shares of common stock in late October 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc. (RCUS), reported the sale of 96,859 shares of common stock.
• The sales occurred on October 28, 2025, and October 29, 2025.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Jaen on August 12, 2024.
• The shares were sold at weighted average prices ranging from $20.1874 to $22.0441.
• Following these transactions, Mr. Jaen beneficially owns 1,458,594 shares, comprising 1,091,374 shares indirectly through a trust and 367,220 shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the pre-planned nature under a Rule 10b5-1 plan suggests a routine personal financial management decision rather than a reaction to adverse company-specific news.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not a reaction to recent undisclosed company news.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Risks

• No specific risks were detailed in this Form 4 filing beyond the general market perception associated with insider stock sales.

Future Outlook

This filing does not provide forward-looking statements or guidance beyond the reporting of past, pre-planned stock transactions.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024.

Industry Context

Insider stock sales, particularly by senior executives, are a common occurrence across all industries. The use of a Rule 10b5-1 trading plan is a standard practice for insiders to sell shares in an orderly fashion while mitigating concerns about trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for insider stock sales is a widely accepted corporate governance practice, aligning with industry standards for transparent and pre-planned equity dispositions by executives.
• The volume of shares sold represents a portion of the executive's total holdings, which is typical for personal financial management rather than a complete divestment.

Corporate Governance

Related Party Transactions

• The reported sales of common stock by Juan C. Jaen, President of Arcus Biosciences, Inc., constitute related party transactions as they involve a key executive of the company.

Stakeholder Impact

• Shareholders may interpret insider selling as a signal, though the pre-planned nature under a 10b5-1 plan mitigates concerns that the sales are based on undisclosed negative information.
• Employees are generally not directly impacted by routine insider stock sales.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the reported transactions.

Key Dates

Recommendation

While insider selling by a President can be a data point for investors, the fact that these sales were pre-planned under a Rule 10b5-1 plan adopted over a year prior suggests they are part of a personal financial strategy rather than a reaction to new, material company developments. Therefore, this filing alone does not warrant a strong buy or sell recommendation, but rather suggests a 'hold' as investors should continue to monitor broader company performance and market conditions.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Juan C. Jaen, President, Equity